IBD
Resources and insights tagged di ibd from Pedestal Health.
Publications
19
Total Publications
5
Abstract/Manuscript
1
Oral Presentation
13
Poster Presentation
2026 · Poster Presentation · AbbVie · Gastroenterology
Characterization and Impact of Risankizumab on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO
Read more →2026 · Poster Presentation · AbbVie · Gastroenterology
Characterization and Impact of Upadacitinib on patients with Fistulizing Crohn’s Disease in the Real World: Findings from TARGET-GASTRO
Read more →2026 · Poster Presentation · Merck · Gastroenterology
Impact Of Early Endoscopic Remission After Advanced Therapy On Long-Term Complications In Crohn's Disease: Findings From TARGET-IBD
Read more →2024 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Factors Predicting Loss of Remission in Crohn's Disease Patients in Endoscopic Remission in the Real World Results From TARGET-IBD
Read more →2023 · Abstract/Manuscript · University of North Carolina at Chapel Hill
Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
Read more →2022 · Poster Presentation · University of Chicago · Gastroenterology
The Impact of Early vs. Late Biologic Initiation Among Real World Patients with Crohn's Disease in TARGET IBD
Read more →2022 · Abstract/Manuscript · Atrium Health
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
Read more →2021 · Poster Presentation · University of North Carolina at Chapel Hill · Gastroenterology
Histological Inflammation Predicts Loss of Remission Among Crohn's Patients with Endoscopic Remission: A US Cohort Analysis
Read more →2021 · Poster Presentation · University of North Carolina at Chapel Hill · Gastroenterology
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort
Read more →2021 · Poster Presentation · AbbVie Inc. · Gastroenterology
Biologic-naïve Patients with Crohn's Disease are More Likely to Achieve Mucosal Healing than Biologic-experienced Patients: TARGET-IBD Real World Cohort
Read more →2021 · Abstract/Manuscript · Atrium Health
Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease
Read more →2021 · Abstract/Manuscript · University of Chicago
Methodology and initial results from a real-world observational cohort of patients with inflammatory bowel disease: TARGET-IBD
Read more →2020 · Poster Presentation · Atrium Health · Gastroenterology
Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD
Read more →2020 · Oral Presentation · Gastroenterology
Objective Disease Activity Assessment and Therapeutic Drug Monitoring is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD
Read more →2020 · Poster Presentation · Atrium Health · Gastroenterology
Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study (ECCO)
Read more →2020 · Poster Presentation · Atrium Health · Gastroenterology
Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort (ACG)
Read more →2019 · Poster Presentation · Atrium Health · Gastroenterology
Oral Mesalamine Use in Crohn's Disease After Implementation of the American College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study (ACG)
Read more →2019 · Poster Presentation · Gastroenterology
Medication Use and Comorbidities Among Elderly as Compared to Younger Patients with Inflammatory Bowel Disease in the TARGET-IBD Cohort
Read more →2018 · Poster Presentation · Atrium Health · Gastroenterology